Generation of novel bone forming cells (monoosteophils) from LL-37 treated monocytes
In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils.
1. A method of producing a population of monocyte-derived bone-forming cells, the method comprising:
isolating a population of monocytes from a blood sample from a subject;
and
culturing the isolated monocytes in the presence of an effective dose of LL-37 until they differentiate into the population of monocyte-derived bone-forming cells.
2. The method of claim 1 , wherein the effective dose of LL-37 is between about 1.25 μM and 10 μM.
3. The method of claim 1 , wherein the effective dose of LL-37 is 5 μM.
4. The method of claim 1 , wherein the blood sample is obtained from a subject in need of bone repair.
5. The method of claim 1 , wherein the blood sample is obtained from a donor subject.
6. A monocyte derived bone-forming cell population produced by the method of claim 1 .
7. The monocyte-derived bone-forming cell population of claim 6 , wherein the cell population expresses osteocalcin (OC), osteonectin (ON), bone sialoprotein II (BSP II), osteopontin (OP), RANK, RANKL, MMP-9, tartrate resistant acid phosphatase (TRAP), and cathepsin K (CK).
8. The monocyte-derived bone-forming cell population of claim 6 , wherein the effective dose of LL-37 is between about 1.25 μM and 10 μM.
9. The monocyte-derived bone-forming cell population of claim 6 , wherein the effective dose of LL-37 is about 5 μM.